(Circulation. 1999;99:713-720.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Clenbuterol Increases Stroke Power and Contractile Speed of Skeletal Muscle for Cardiac Assist
From Imperial College, National Heart and Lung Institute, London, UK.
Correspondence to Prof Sir Magdi Yacoub, Department of Cardiac Surgery, Royal Brompton Hospital, Sydney St, London SW3 6NP, UK.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Skeletal muscle assist (SMA) may be limited by loss of power, slowing of contraction and relaxation, and atrophy of the transformed latissimus dorsi muscle (LD). Clenbuterol (clen), a ß2-adrenergic receptor agonist, was used to improve the performance of trained skeletal muscle in sheep.
Methods and Results—The following 4 groups were used: A
(n=6), untrained controls; B (n=6), left LD progressively transformed
toward a slow-twitch and fatigue-resistant phenotype by
electrical stimulation over 12 weeks (2.5 to 5 V, 240-µsec pulse
duration, 35 Hz, 3 to 6 pulses per burst, and up to 40 bursts per
minute); C (n=6), clen-treated (0.5 mg/kg SC) for 12 weeks; and D
(n=6), clen+trained. In a terminal experiment, the mobilized LD was
wrapped around a rubber aorta of a mock circulation and stimulated to
contract 40 times per minute. Group A had an initial mean pressure
augmentation (
P) of 24.6 mm Hg and stroke power of 2.28 W/kg,
but both fell to <20% of their original values by 15 minutes because
of fatigue (P<0.005). Group B was
fatigue-resistant, with a P and stroke power at 60 minutes
of 13 mm Hg (70% of initial) and 0.34 W/kg (39% of initial),
respectively. The performance of group C was similar to that of
controls. In group D, however, the muscles were stronger at all time
points than in B, with a P of 23 mm Hg and stroke power of
2.66 W/kg at 60 minutes (P<0.01). The speeds of
contraction (+dP/dt:P) and relaxation (-dP/dt:P) were
significantly greater in group D than B. Protein analyses
showed group D to have only a trend toward greater abundance of the
fast isoforms of myosin heavy chain and sarcoplasmic reticulum
Ca2+-ATPase (P>0.1).
Conclusions—Clen improves the performance of trained skeletal muscle in a model of aortomyoplasty by unknown mechanisms. These findings may have important implications in SMA.
Key Words: muscles • circulation • clenbuterol
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Skeletal muscle assist (SMA) is an attractive technique for the treatment of end-stage cardiac failure that uses autologous muscle wrapped around the heart or major vessels and stimulated to contract in systole (cardiomyoplasty) or diastole (aortomyoplasty).1 2 More than 600 cardiomyoplasties have been performed to date, although their efficacy remains to be established.3 The long-term performance of the latissimus dorsi muscle (LD) is vital, yet this is far from optimal. For example, morphological and biochemical abnormalities are known to occur in the skeletal muscle of patients with end-stage heart failure and may persist despite normalization of central hemodynamics.4 Chronic electrical training transforms the LD from a predominantly fast-twitch to slow-twitch phenotype. This induces the fatigue resistance necessary for long-term assist but also produces deleterious effects, such as a fall in stroke power5 and slowing of contraction and relaxation.6 These changes are associated with fast-to-slow transitions in myosin heavy chain (MHC) isoform abundance, although the concomitant changes in the expression of Ca2+-regulatory proteins, such as sarco(endo)-plasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB), are less well characterized.7 Finally, atrophy and lipomatosis occur as late sequelae of cardiomyoplasty.8
Several approaches have been suggested to compensate for these deleterious changes (reviewed in Reference 99 ). Androgenic anabolic steroids have been investigated with varying success.10 11 Furthermore, their known serious side effects12 prohibit long-term use.
Chronic administration of ß2-adrenergic receptor agonists, such as clenbuterol (clen), induces muscle hypertrophy,13 including untrained LD in the rat.14 Zeman et al15 have shown clen to induce a slow-to-fast fiber type transition and increased tetanic tension and twitch speeds. These changes were most marked in the maturing rat soleus, in which clen retarded the natural fast- to slow-twitch fiber transition seen during the first 8 to 12 weeks after birth. The functional effects of clen on mature fast-twitch skeletal muscle undergoing similar changes in fiber composition due to progressive electrical training, however, are unknown.
We have tested the hypothesis that clen induces beneficial changes in the physiological and biochemical characteristics of trained skeletal muscle.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animal Groups
Twenty-four Welsh Mountain ewes with a mean BW of 34 kg (range, 25 to 40 kg) were cared for in accordance with guidelines laid down by the Home Office of Great Britain and Northern Ireland (1986). All were housed in a 12-hour light-dark cycle and given feed and water ad libitum. After 1 to 2 weeks of settlement, they were randomly assigned to 4 groups: group A (n=6), controls: daily subcutaneous (SC) injections of sterile water 0.5 mL for 12 weeks; group B (n=6), trained: 2 intramuscular electrodes implanted into the left LD muscle and a myostimulator (Telectronics Pacing Systems Inc) inserted into a subcutaneous pocket in the interscapular region under general anesthesia. Progressive training was commenced 48 hours later using the stimulation parameters given in Table 1
. LD twitch remained visible, and
0.5 mL of sterile water was injected daily; group C (n=6) was treated
with clen 0.5 mg/kg body wt (BW) twice daily SC for 12 weeks; and
finally, group D (n=6), training plus clen administration. All
injections commenced on the day the myostimulator was programmed
"on." Only groups B and D were operated on; groups A and C were not
subjected to sham operations. Our studies therefore make the assumption
that dummy leads within the LD do not significantly alter the structure
and function of the LD. This is one important limitation of our
study.
|
Clen Administration
Clen free base (donated by Boehringer-Ingelheim, UK) was
dissolved in sterile water to 10 mg/mL and stored at 4°C. Animals in
C and D were given a challenge dose of 2 mg SC to induce tachyphylaxis,
a characteristic property of ß-agonists, thus protecting against the
subsequent larger treatment doses (0.5 mg/kg BW). Changes in
arterial blood pressure are shown in Figure 1.
|
indicates systolic blood pressure; 
, diastolic
blood pressure; and 
, heart rate.
Assessment of LD Performance
After 12 weeks, all animals underwent general
anesthesia. Muscle relaxants were omitted. The ruminant
stomach was decompressed with a 12-bore orogastric tube.
Intravenous fluid maintenance was in the form of
5% dextrose solution at 100 mL/h. Arterial oxygen
saturation was monitored with a pulse oximeter and maintained between
96% and 100%. Core temperature was maintained at 38±1°C with
warming blankets. Only the left LD was assessed functionally in all
groups.
Maximum Linear Isometric Force
An isometric force transducer (Logan-Sinclair Research) was
fixed to the head end of the operating table, the abducted-flexed left
forelimb was tied securely to it, and the resting tension was set at a
baseline of 10 N. This value was determined by measuring the maximum
developed force after a brief period of stimulation (5 V, 35 Hz, 6
pulses per burst, 240-µs pulse duration) at different preload
tensions (0 to 50 N). This is in agreement with that reported by
Kochamba and Chiu.16
Wrap Performance on the Mock Circulation System
The design and validation of the mock circulation system (MCS)
used was described previously.17 The myostimulator was
programmed "off," and the left LD was mobilized on its intact
neurovascular pedicle and tendon and wrapped around the latex aorta of
the MCS. The stimulator was programmed "on" at a rate of 40 bursts
per minute against a baseline pressure of 70 mm Hg under the
stimulation parameters used for the final month of training
(see Table 1
). Pressure waveforms were recorded at 1, 5, and
15 minutes and every 15 minutes thereafter for a total of 60 minutes. A
lethal dose of anesthetic was then administered, and the left and right
LDs were dissected out and weighed. Biopsies were taken from standard
sites for histological examination and biochemical
analyses.
Data Acquisition, Storage, and Analysis
The pressure-wave signal was amplified and converted from
analog to digital form and visualized on a PC loaded with Spike 2
(Cambridge Electronics). This interactive software package allows
measurement of pressure augmentation (P), stroke volume (SV),
contraction time (Ct, ie, time to peak pressure),
relaxation time (Rt90, ie, time from peak
pressure to 90% decay), and the maximum rates of pressure generation
(+dP/dt) and decay (-dP/dt). Mean energy (E) generated over the
shortening phase of contraction at 35 Hz, involving the muscle working
as a pressure generator against a 70 mm Hg preload, was
calculated from the product of mean P and SV. The stroke power
was calculated from E/Ct. Peak energy per
contraction was not measured, because it overestimates the true
performance (Stanley Salmons, PhD, 1995, personal
communication).
The mean and SEM for all these parameters were calculated from 6 to 8 waves at each time point of measurement.
Immunocytochemistry
Serial cross sections 8 µm thick from frozen LD
were cut and mounted. Monoclonal antibodies (Novacastra Laboratories
Ltd) for fast (types IIa and IIb; 1:300 dilution) and slow (1:100
dilution) myosin were used to determine the relative frequencies of
fast and slow fibers. An antibody for spectrin (1:200 dilution) was
used to stain the sarcolemma and delineate the cells more clearly.
Control slides were treated similarly but with the primary antibody
replaced by diluent alone to establish the specificity of
immunostaining. Fiber-type frequency and
cross-sectional areas were analyzed with the Lucia M Image
Analysis System (Nikon, UK, Ltd). Five random fields per
section at x100 magnification were analyzed from LD samples
taken from 4 animals in each group. A number ranging from 850 to 2200
cells per group was thus available for statistical analyses.
Protein Chemistry
Frozen samples of LD stored at -70°C were analyzed
for MHC, SERCA, and PLB isoforms. The relative abundance of these is
known to change in compensatory overload18 and stretch
hypertrophy.19 Other proteins, such as the
troponins, and their calcium-binding properties are also important,
although we did not investigate these. Left ventricular and
atrial tissues from clen-treated and control animals were
analyzed for cardiac atrial natriuretic factor
(ANF). Ventricular reexpression of ANF is a useful marker
of cardiac hypertrophy.14
Crude MHC extracts were prepared and protein concentrations determined according to the method of Bradford.20 The MHC isoforms were separated by 1-dimensional SDS-PAGE (150x60x0.5 mm) using a modification of the method of Talmadge and Roy.21 PLB, SERCA, and ANF proteins were separated with 12% wt/vol acrylamide-bis gels (150x160x1.5 mm) according to the method of Ossipow et al.22
Western blot membranes were stained, scanned, and analyzed with the Quantity One software package (Protein and DNA Imageware).
Statistics
Comparisons between the 4 groups were made by ANOVA, and
the Kruskal-Wallis post hoc test was applied for
nonparametric data. For comparisons of data from 2 separate
time points within the same group, Student's t test was
used. All data are presented as mean±SEM, and results were
considered significant at values of P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Surgical
All animals in groups B and D survived surgery and grew normally during the 12-week training period. There were no cases of device failure. One animal in D developed a severe wound infection and was euthanized. The remaining 23 animals were stable during the 3 hours of anesthesia for the assessment of LD performance.
BW, LD Weight, and Heart Mass
Table 2 shows that sheep treated
with clen (C and D) had a lower initial mean BW than those not
receiving the drug (A and B). All were on the same part of the growth
curve for Welsh Mountain sheep, but the mean rate of weight gain was
significantly greater for C+D than for A+B (920 versus 675 g/wk
[P<0.01], respectively). This is in keeping with the
known growth-promoting effects of clen.13
|
LD hypertrophy was in proportion to the increase in BW in
all groups, ie, the LD/BW ratio was similar (P>0.2). The
left and right LDs weighed approximately the same in all groups, with
the exception of D, in which the combination of clen and training
resulted in the left LD being 18% heavier than the right LD
(P<0.05). Interestingly, the exsanguinated heart
mass–to-BW ratio was greater in animals that were trained (B and D)
than in the nontrained groups (A and C) (P<0.05), and clen
did not appear to affect this parameter. Results are
summarized in Table 2.
Linear Performance
The peak force generated in response to a standard burst
stimulation relevant to clinical cardiac assist (ie, 35 Hz, 170 ms)
was 86.3±6.7 N/kg in group B and 159.5±12.8 N/kg in A
(P<0.001), ie, a 46% reduction with training. C produced
only a small increase in linear isometric force (170±17.2 N/kg)
compared with controls (P>0.1). In D, however, 145±18.1
N/kg was generated, much higher than with training alone
(P<0.05). These data should be interpreted cautiously,
however, because the development of maximum force by trained and
untrained muscle may require a different duration of tetanic
stimulation, a parameter we did not vary.
Wrap Performance
P and Fatigability
P in group B was 19.9±2.4 mm Hg at the start and
12.5±1.1 mm Hg at 15 minutes, which was maintained throughout 60
minutes, consistent with fatigue-resistant work (see
Figure 2A). In contrast, the initial P
in A was 24.6±0.9 mm Hg (P<0.05), although this was
not maintained beyond 5 minutes because of fatigue. By 15 minutes, P
declined to 25% of its initial value (P<0.001). Muscles in
group C were more effective than in controls in that P was
32.9±4.2 mm Hg, but they also fatigued within 15 minutes. Group
D produced the highest P at all time points and at 60 minutes was
23.6±4.9 mm Hg (P<0.002). In addition, clen did not
affect fatigue resistance in this group. Figure 2B shows
representative pressure waves.
|
)
and clen-treated (
) muscles fatigued within 5 minutes. At 60
minutes, clen+trained (
) LDs generated greater augmentation per
contraction than trained only (
Stroke Volume
There was an acute drop in SV in group A from 21.1±0.7 to
7.9± 1.4 mL in the first 5 minutes (P<0.01). A similar
drop was observed in C. By 60 minutes, the SV in both groups was <5
mL, compared with B, which gave 10.9±1.35 mL per contraction
(P<0.02). However, the wraps from D generated the greatest
SV beyond 5 minutes (21.5 to 24.3 mL, P<0.001).
Stroke Power
At the start, the stroke power was 61% lower in group B than in
the prefatigued controls (P=0.007) (Figure 2C). In
group D, the stroke power at 1 minute was 3.79±0.71 W/kg, compared
with 0.88±0.2 W/kg in B (P<0.001). This difference
persisted so that at 60 minutes, the stroke power done by B was
0.34±0.08 W/kg, compared with the much higher value produced by D of
2.66±0.87 W/kg.
Contraction
Ct at the start was 135.1±8.8
and 243.2±6.1 ms in groups A and B, respectively (P<0.001)
(see Figure 3A). Similarly, the
+dP/dt:P ratio was more than twice as great in A as B
(P<0.01) (see Figure 3B).
|
Ct in group C was similar to that in
controls (P>0.2), although the +dP/dt:P was greater in
the former at 15 minutes but not beyond (P<0.05; Figure 3B). Group D had faster contractile characteristics than B (see
Figures 3A and 3B).
It is noteworthy that both Ct and +dP/dt:P did
not vary significantly throughout the 60 minutes in all groups.
Relaxation
Rt90 at the start was 115.4±7.2 and
249.2±35.2 ms in groups A and B, respectively (P<0.05)
(see Figure 4A). Similarly, the
-dP/dt:P was greater in A than B (P<0.05) (see Figure 4B). By 15 minutes, however, coincident with the onset of
fatigue, the Rt90 increased significantly in A,
to 205.4±13.9 ms (P<0.001) (see Figure 4A),
resulting in a fall in the
Ct:Rt90 ratio of 1.20 to
0.64 (P<0.001). In contradistinction, this ratio remained
unchanged in the trained muscles throughout the period of testing.
|
Group C had faster relaxation than A during the first 15 minutes
(P<0.01) but had similar Rt90 values
thereafter (Figure 4A). In addition, both demonstrated a similar
fall in Ct:Rt90 associated
with the onset of fatigue. Quite strikingly, there was a 96% reduction
in the Rt90 throughout 60 minutes in group D
compared with B (see Figure 4A). Similarly, -dP/dt:P was
greater in D than in B (P<0.001), as seen in Figure 4B.
The Rt90 did not change significantly throughout the 60 minutes of hemodynamic augmentation in fatigue-resistant muscles (ie, groups B and D).
Histology
In group A, 77% of fibers were immunoreactive to fast myosin,
with almost complete fast-to-slow transition with electrical training
(group B; see Figure 5A through 5I). The
fast fibers had a mean cross-sectional area of 4458±72
µm2 in A compared with 1668±146
µm2 in B (P<0.001). Similarly, the
slow fibers measured 6606±233 µm2 in A
and 3941±47 µm2 in B
(P<0.001). In C, fast fibers were hypertrophied
(8812±193 µm2) compared with A, without a
significant change in slow fibers (5760±236
µm2). In D, both fast (6340±308
µm2) and slow (4647±74
µm2) fibers were hypertrophied compared with B
(P<0.001).
|
Protein Chemistry
No differences were observed between left LD and right LD samples
in group A (P>0.4), and data from these muscles were pooled
(see Table 3). In B, only the left LD
muscles were subjected to electrical training, with the right LD acting
as the internal control. In this group, the right LDs were not
significantly different from control group A values for any of the
proteins. In C, both left and right LDs were clen-treated and
untrained. No significant differences between them were observed, and
data from both were pooled. In D, only the left LDs were subjected to
clen and electrical training, with the right LDs acting as the internal
clen-only controls. The right muscles in D were not significantly
different from those in C for any protein studied except SERCA 2A
(P<0.05).
|
Myosin Heavy Chain
Fast MHC was predominant in group A (78.5%) compared with
slow MHC (P<0.01); see Table 3. In B, the major
isoform in the left (trained) LD was slow MHC (99.6%) compared with
the right (untrained) LD (P<0.001). Clen in group C
increased the proportion of fast MHC to 89.1% compared with A
(P<0.01). In D, the left LD expressed less fast MHC isoform
(10.6%) compared with A and C (P<0.001 and
P<0.001, respectively). A trend toward a reduced abundance
of slow MHC (89.4%) was observed in D compared with B (99.6%).
SERCA
A trend toward higher levels of fast SERCA 1 was observed in
group A compared with untrained right LD from B. Training (B, left LD)
reduced the abundance of the fast SERCA 1 (P<0.001) without
a significant change in the level of slow SERCA 2a compared with A; see
Table 3. In contrast, clen treatment alone (C) had no
significant effect on SERCA 1 but resulted in a decrease in SERCA 2A
compared with group A (P<0.01). The combination of clen and
training (D, left LD muscles) significantly reduced the level of SERCA
1 compared with C (P<0.003) and A (P<0.005).
Only a trend toward increased SERCA 1 was observed in B. In D, SERCA 2A
was unchanged compared with A and B but higher than C
(P<0.01).
Phospholamban
Group B contained higher PLB levels (0.54 optical density
arbitrary units) than group A (P<0.001, Table 3). In
C, PLB (0.07 optical density arbitrary units) was reduced compared with
A (P<0.05). The level of PLB in D was intermediate compared
with A and B.
Atrial Natriuretic Factor
ANF was undetectable in left ventricular extracts
taken from groups A and C. Atrial extracts (ANF expression high) from
the same animals provided the positive controls. Unfortunately, we have
not defined the lower sensitivity of detection of ANF in our system.
With a standard loading of 25 µg protein, no signal was observed in
any left ventricular samples, whereas the equivalent
loading of atrial samples always resulted in a strong positive band.
However, we did not do any formal quantification of ANF.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The addition of a myotrophic stimulus to electrical training is an attractive proposition to enhance the performance of the muscle graft used in SMA. We have shown that the ß2-adrenergic receptor agonist clen improves the stroke power of the trained LD during a period of sustained activity on an MCS that mimics the wrap configuration and loading conditions of aortomyoplasty. In addition, significant increases in the rates of tension development and decay were demonstrated. These are potentially desirable effects in the setting of SMA and were induced without any compromise in fatigue resistance.
The mechanism by which cardiomyoplasty provides hemodynamic benefit is unknown, but it includes systolic augmentation of the ventricle, reduction of wall tension, and prevention of ventricular dilatation. All may contribute to various degrees, although we believe the first to be more important and postulate that enhancement of stroke power should translate into hemodynamic benefit. Clinical efficacy, in turn, must depend on long-term muscle structure and function as well as its mechanical coupling to the circulation. The latter is the work transferred from the muscle to the circulation (available stroke work) and is most usefully measured in an in vivo model of aortomyoplasty.
The cause of LD atrophy in cardiomyoplasty patients is multifactorial. Surgical mobilization renders muscle and nerve fibers ischemic, particularly in the distal segment. Once translocated into the mediastinum, the LD is wrapped around the heart with a reduced resting tension, where it remains inactive for 2 weeks to allow its fusion to the epicardium. Atrophy secondary to reduced stretch and disuse may result. Later, further atrophy due to a shift from a predominance of type II (large-diameter) to type I (small-diameter) fibers with electrical transformation may occur. Indeed, up to 60% atrophy may occur 2 to 4 years after cardiomyoplasty.8
The growth-promoting effect of clen is not confined to normal skeletal muscle but is also evident in certain states of altered physiology and even pathology. For example, it has been shown to inhibit and reverse denervation23 and disuse24 atrophy. It also induces beneficial changes in the mdx mouse.25 The model used in our study, however, uses in situ training of the LD, believed to be associated with minimal atrophy and lipomatosis. Therefore, the potential benefits of clen need to be studied on in vivo wraps.
Preservation of fast-twitch physiology is theoretically desirable for both cardiomyoplasty and aortomyoplasty. Up to 30% of patients with end-stage heart failure have pure diastolic dysfunction (ie, ejection fraction >40%), and most of the remainder have both systolic and diastolic dysfunction.26 Wrapping these ventricles with a layer of skeletal muscle that is sluggish to relax may impose a restrictive physiology that may greatly limit the efficacy of SMA. Similarly, effective left ventricular afterload reduction can occur in aortomyoplasty only if the muscle is able to relax rapidly. Our study demonstrates the ability of clen to improve LD performance by significantly increasing stroke power and contractile speed. However, our findings are limited to growing sheep with normal hearts. Because the safety and tolerance of clen in heart failure is unknown, future work should be directed toward evaluating this agent in a model of heart failure.
Fast isoforms of MHC and SERCA were found to be more abundant with clen treatment. These were very modest changes, however, and probably do not account for the much larger increases in power and speed of contraction and relaxation observed. Moreover, they were not significantly changed in group D, indicating that training exerts a more dominant effect on gene expression than the concomitant pharmacological stimulus. Hypertrophy per se could not account for these changes either, because changes in intrinsic characteristics (ie, normalized for mass) were observed. Therefore, other as yet unknown mechanisms may be involved, possibly involving ß2-adrenergic receptor activation and associated transduction pathways. The role of ß2-adrenergic receptors in the growth-promoting effect of clen, however, remains controversial, although acute administration of other ß2-agonists enhances excitation-contraction coupling in isolated skeletal muscle preparations.27 We can only speculate that a similar effect may be occurring in our chronic in vivo model. Further studies are needed to characterize changes in ß-adrenergic receptor density and affinity associated with electrostimulation, as well the transduction pathways that may alter the efficiency of the contractile mechanism.
Several issues need to be addressed before clen can be considered as an adjunct to clinical SMA. For example, although its acute chronotropic effects on the human heart are predictable on the basis of its known ß2 effects, the effects of long-term administration are unknown. In a previous study, we observed an increase in heart mass by 18% in the rat, with molecular changes typical of "physiological" hypertrophy, after clen treatment for 21 days.14 There are no cited reports of clen-induced cardiac hypertrophy in large mammalian species, including humans, and in the present study we were unable to detect ANF in the ventricles of clen-treated sheep. The effects of clen on the failing heart, however, are completely unknown and need to be investigated in appropriate animal models. It is noteworthy that hearts from trained animals are significantly heavier than those in controls, the mechanism of which is unclear, although it may involve a cardiotrophic mediator elaborated and secreted by exercising skeletal muscle. Similarly, a nonsignificant trend toward a greater abundance of SERCA 1 was observed in control left LD compared with right LD taken from group B animals, in which the left LD was chronically trained. We cannot exclude the possibility that the chronically exercising muscle exerts a systemic effect on other skeletal muscles; this also warrants further investigation.
The limitations of our study include the following.
1. We assume that dummy leads would not significantly alter the
integrity of the LD. We found it impractical to use a larger number of
animals to include a sham group. Subsequent data from the protein
chemistry analyses, however, showed that the right LD
(unstimulated) taken from trained animals (ie, left LD electrically
trained for 12 weeks) was phenotypically identical to left LD taken
from control animals (see Table 3).
2. The changes in contractile properties seen in muscles treated with clen may be associated with alterations in the levels of other proteins, such as the troponins, and their calcium-binding properties, although we did not investigate these.
3. The hemodynamic data from the MCS may not translate clinically and need to be validated in an in vivo model of aortomyoplasty.
4. The acute and chronic effects of clen in animals with heart failure were not investigated, and future work should be directed to this before the potential clinical use of this ß2-adrenergic receptor agonist can be considered for improving the results of SMA.
In conclusion, clen improves the biomechanical properties of transformed LD in an ex vivo model of aortomyoplasty. Stroke power was increased by 4-fold, and contraction and relaxation times were reduced by 96% and 105%, respectively. These muscles remained fatigue-resistant despite these alterations. The observed trend toward increased abundance of the fast isoforms of MHC and SERCA probably does not explain the more significant functional alterations. There was no evidence of concomitant cardiac hypertrophy. This study may have important implications for the use of pharmacological agents to optimize the performance of electrically transformed skeletal muscle.
|
Acknowledgments |
|---|
This work was supported by Telectronics Pacing Systems Inc. We thank Professor Colin Green and his team at Northwick Park Institute of Surgical Research for excellent technical assistance. A special thanks to Dr Charlotte Maltin for advice with the experimental design.
Received April 22, 1998; revision received September 9, 1998; accepted September 25, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Hooper TL, Stephenson LW. Using skeletal muscle to assist the heart. Br Heart J. 1991;66:261–263.
2. Cumming DVE, Shah SS, Sinclair RL, Pattison CW, Pepper JR, Yacoub MH. Skeletal muscle counterpulsation. Basic Appl Myol. 1992;2:73–81.
3.
El Oakley RM, Jarvis JC. Cardiomyoplasty: a critical
review of experimental and clinical results. Circulation. 1994;90:2085–2090.
4.
Stratton JR, Kemp GJ, Daly RC, Yacoub M, Rajagopalan
B. Effects of cardiac transplantation on bioenergetic abnormalities of
skeletal muscle in congestive heart failure. Circulation. 1994;89:1624–1631.
5. Salmons S, Jarvis JC. The working capacity of skeletal muscle transformed for use in a cardiac assist role. In: Transformed Muscle for Cardiac Assist and Repair. Mount Kisko, NY: Futura; 1990:89–104.
6.
Trumble DR, Magovern JA. Ergometric studies of
untrained skeletal muscle demonstrate feasibility of muscle-powered
cardiac assistance. J Appl Physiol. 1994;77:2036–2041.
7. Salmons S, Henriksson J. The adaptive response of skeletal muscle to increased use. Muscle Nerve. 1985;4:94–105.
8. Kalil-Filho R, Bocchi E, Weiss RG, Rosenberg L, Bacal F, Moreira LFP, Stolf NAG, Magalhaes AAC, Bellotti G, Jatene A, Pileggi F. Magnetic resonance imaging evaluation of chronic changes in latissimus dorsi cardiomyoplasty. Circulation. 1994;90(pt 2):II-102–II-106.
9. Petrou M, Boheler KR, Yacoub M. Induction of skeletal muscle hypertrophy: its relevance to skeletal muscle assist. In: Yacoub M, Pepper JR, eds. Annual of Cardiac Surgery. 8th ed. 1995:47–55.
10. Salmons S. Myotrophic effects of anabolic steroids. Vet Res Commun. 1983;7:19–26.[Medline] [Order article via Infotrieve]
11. Fritzsche D, Krakor R, Asmussen G, Lange S, Kaufmann A, Zapf P, Mehlhorn G, Berkei J, Wigera R. Effect of an anabolic steroid (metenolon) on contractile performance of the chronically stimulated latissimus dorsi in sheep. Eur J Cardiothorac Surg. 1994;8:214–219.[Abstract]
12. Carrasco D, Prieto M, Pallardo L, Moll JL, Cruz JM, Munoz C, Berenguer J. Multiple hepatic adenoma after long-term therapy with testosterone enanthate: review of the literature. J Hepatol. 1985;1:573–578.[Medline] [Order article via Infotrieve]
13. Kim YS, Sainz RD. ß-Adrenergic agonists and hypertrophy of skeletal muscles. Life Sci. 1992;50:397–407.[Medline] [Order article via Infotrieve]
14. Petrou M, Wynne DH, Boheler KR, Yacoub M. Clenbuterol induces hypertrophy of the latissimus dorsi and heart in rat coincident with molecular and phenotypic changes. Circulation. 1995;92(suppl II):II-483–II-489.
15.
Zeman RJ, Ludemann R, Easton TG, Etlinger JD. Slow to
fast alterations in skeletal muscle fibres caused by clenbuterol,
a ß2-receptor agonist. Am J
Physiol. 1988;254:E726–E732.
16. Kochamba G, Chiu RC-J. The physiologic characteristics of transformed skeletal muscle for cardiac assist. ASAIO Trans. 1987;33:404–407.[Medline] [Order article via Infotrieve]
17.
Petrou M, Bowles C, Yacoub M. Comparative study of the
biomechanical properties of trained and untrained skeletal muscle.
Cardiovasc Res. 1997;33:583–592.
18. Kandarian SC, Peters DG, Taylor JA, Williams JH. Skeletal muscle overload upregulates the sarcoplasmic reticulum slow calcium pump gene. Am J Physiol. 1994;266(Cell Physiol 35):C1190–C1197.
19. Loughna PT, Izumo S, Goldspink G, Nadal-Ginard B. Disuse and passive stretch cause rapid alterations in expression of developmental and adult contractile protein genes in skeletal muscle. Development. 1990;109:217–223.[Abstract]
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem. 1975;72:248–254.
21.
Talmadge RT, Roy PR. Electrophoretic separation of rat
skeletal muscle myosin heavy-chain isoform. J Appl
Physiol. 1993;75:2337–2340.
22.
Ossipow V, Laemmli UK, Schibler U. A simple method to
renature DNA-binding proteins separated by SDS-polyacrylamide
gel electrophoresis. Nucleic Acids Res. 1993;21:6040–6041.
23. Maltin CA, Reeds PJ, Delday MI, Hay SM, Smith FG, Lobley GE. Inhibition and reversal of denervation induced atrophy by the beta-agonist growth promoter, clenbuterol. Biosci Rep. 1986;6:811–818.[Medline] [Order article via Infotrieve]
24.
Delday MI, Maltin CA. Clenbuterol increases the expression of
myogenin but not myoD in immobilized rat muscles. Am J
Physiol. 1997;272:E941–E944.
25. Dupont-Vesteegden EE, Katz MS, McCarter RJ. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice. Muscle Nerve. 1995;18:1439–1447.
26. Dougherty AH, Naccarelli GV, Gray EL, Hicks CH, Goldstein RA. Congestive heart failure with normal systolic function. Am J Cardiol. 1984;54:778–782.[Medline] [Order article via Infotrieve]
27. Cairns SP, Dulhunty AF. ß-Adrenergic potentiation of E-C coupling increases force in rat skeletal muscle. Muscle Nerve. 1993;16:1317–1325.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K.R. Soppa, J. Lee, M. A. Stagg, L. E. Felkin, P. J.R. Barton, U. Siedlecka, S. Youssef, M. H. Yacoub, and C. M.N. Terracciano Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure Cardiovasc Res, March 1, 2008; 77(4): 695 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsuneyoshi, W. Oriyanhan, H. Kanemitsu, R. Shiina, T. Nishina, S. Matsuoka, T. Ikeda, and M. Komeda Does the {beta}2-Agonist Clenbuterol Help to Maintain Myocardial Potential to Recover During Mechanical Unloading? Circulation, August 30, 2005; 112(9_suppl): I-51 - I-56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Burniston, L.-B. Tan, and D. F. Goldspink {beta}2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle J Appl Physiol, April 1, 2005; 98(4): 1379 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. R. Soppa, R. T. Smolenski, N. Latif, A. H. Y. Yuen, A. Malik, J. Karbowska, Z. Kochan, C. M. N. Terracciano, and M. H. Yacoub Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1468 - H1476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. F. Hon and M. H. Yacoub Bridge to recovery with the use of left ventricular assist device and clenbuterol Ann. Thorac. Surg., June 1, 2003; 75(90060): S36 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K.F. Hon, P. Steendijk, M. Petrou, K. Wong, and M. H. Yacoub Influence of clenbuterol treatment during six weeks of chronic right ventricular pressure overload as studied with pressure-volume analysis J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 767 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Trumble and J. A. Magovern Method for measuring long-term function of muscle-powered implants via radiotelemetry J Appl Physiol, May 1, 2001; 90(5): 1977 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. W. Guldner, P. Klapproth, M. Gro{beta}herr, M. Stephan, E. Rumpel, R. Noel, and H.-H. Sievers Clenbuterol-Supported Dynamic Training of Skeletal Muscle Ventricles Against Systemic Load : A Key for Powerful Circulatory Assist? Circulation, May 9, 2000; 101(18): 2213 - 2219. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||